The Evolving Systemic Treatment for Advanced Hepatocellular Carcinoma
Multiple phase III clinical trials have led to the approval of targeted agents and their combinations with immune checkpoint inhibitors, demonstrating meaningful survival gains in patients with advanced hepatocellular carcinoma.
Hepatocellular carcinoma (HCC) is one of the common and fatal malignancies, which remains a global health challenge, with an estimated incidence of more than 1 million cases by 2025. The current major progress has improved the management of patients with advanced disease. Systemic treatments with multitarget agents, antiangiogenics alone or in combination with an immune checkpoint inhibitor (ICI), have been approved following positive results from phase III clinical studies. Several ongoing trials are currently exploring novel combinations and are expected to further change the HCC treatment landscape. In this review, we present all approved targeted agents for advanced HCC with an emphasis on their clinical efficacy and discuss the exciting results of the combination of targeted therapy and ICI. Finally, we also summarize the advances in clinical research for HCC.
Advances in systemic therapies have extended overall survival and improved quality of life for patients with advanced HCC, transforming a historically lethal disease into one with curative‑intent options.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort